Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 14 Apr 2022

Tan Y X, Luo J, Huang J X, Luo D M, Liang H Y, Zhou X, Liu X L, Xu N

Abstract excerpt

Objective: To assess the effect of gene mutations on the efficacy of ruxolitinib for treating myelofibrosis (MF) . Methods: We retrospectively analyzed the clinical data of 56 patients with MF treated with ruxolitinib from July 2017 to December 2020 and applied second-generation sequencing (NGS) technology to detect 127 hematologic tumor-related gene mutations. Additionally, we analyzed the relationship between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Nitriles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Pyrimidines

Share to Technology

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 35680632
DOI: 10.3760/cma.j.issn.0253-2727.2022.04.010
PMCID: PMC9189480

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].PMID 35680632Read ↗

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.Semantic proximity Read ↗

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Semantic proximity Read ↗

[Chinese expert consensus on the clinical application of next-generation sequencing technology in myelodysplastic neoplasms (2026)].Semantic proximity Read ↗

[High-Throughput Sequencing Technology for Detection of Gene Mutations in Myeloid Malignancies and Its Clinical Prognostic Significance].Semantic proximity Read ↗

[Mutation characteristics and prognosis of patients with Fanconi anemia signaling pathway gene mutation myeloproliferative neoplasm].Semantic proximity Read ↗

[Genetic characteristics and prognostic values of RAS mutations in patients with myelofibrosis].Semantic proximity Read ↗

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.Semantic proximity Read ↗

[Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].Semantic proximity Read ↗

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.Semantic proximity Read ↗

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyureaSemantic proximity Read ↗

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.Semantic proximity Read ↗

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.